The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Canaccord Genuity on February 12, 2025. The analyst firm set a price target for $424.00 expecting VRTX to fall to within 12 months (a possible -6.44% downside). 78 analyst firms have reported ratings in the last year.

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by Canaccord Genuity, and Vertex Pharmaceuticals upgraded their hold rating.

The last upgrade for Vertex Pharmaceuticals Inc happened on February 12, 2025 when Canaccord Genuity raised their price target to $424. Canaccord Genuity previously had a sell for Vertex Pharmaceuticals Inc.

The last downgrade for Vertex Pharmaceuticals Inc happened on January 30, 2025 when Wells Fargo changed their price target from $460 to $460 for Vertex Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.

While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a upgraded with a price target of $408.00 to $424.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $453.20, which is out of the analyst’s predicted range.